Phaseline

Companies › Ryvu Therapeutics

Ryvu Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MEN1703 (SEL24, Dapolsertib hydrochloride)
Dual inhibitor of PIM kinases and FLT3
PIM1, PIM2, PIM3, FLT3Phase 2Non-Hodgkin Lymphoma, B-cellDec 2026
RVU120
CDK8 and CDK19 inhibitor
CDK8, CDK19Phase 2Acute Myeloid LeukemiaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06534437MEN1703 (SEL24, Dapolsertib hydrochloride)Phase 2Non-Hodgkin Lymphoma, B-cellOncologyDec 2026
NCT06191263RVU120Phase 2Acute Myeloid LeukemiaOncologyAug 2027

Targets

PIM1 (1) PIM2 (1) PIM3 (1) FLT3 (1) CDK8 (1) CDK19 (1)

Companies with the same targets

Sumitomo Pharma America Daiichi Sankyo Sunshine Lake Pharma Bristol-Myers Squibb Novartis Cullinan Therapeutics Aptose Biosciences Etnova Therapeutics Swedish Orphan Biovitrum Theradex

Companies built like this

Criterium EpicentRx Elpiscience (Suzhou) Biopharma Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Inhibrx Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.